Boehringer Ingelheim Acquires GST to Boost its Stem Cell Capabilities in Animal Health
Shots:
- Boehringer Ingelheim has acquired Global Stem cell Technology (GST) focusing to strengthen its portfolio capabilities to accelerate innovation and growth
- The acquisition follows two years of partnership b/w the companies that brought the first-ever registered stem cell-based veterinary medicine (Arti-Cell Forte) in the EU
- The acquisition of GST will accelerate the development pipeline of Boehringer Ingelheim while maintaining its focus on setting new standards of care for animals. Arti-Cell Forte is testimony to the innovation strength that lies within both companies
Ref: Boehringer Ingelheim | Image: GST
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com